^
Association details:
| Biomarker: | FOLR1 overexpression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | idetrexed (CT900) (Folate receptor 1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Published date:
09/21/2022
Excerpt:
Patients with high-grade serous ovarian cancer were enrolled in the expansion cohorts....Thirty-eight response-evaluable patients in the expansion cohorts receiving 12 mg/m2/q2Wk had tumor evaluable for quantification of α-FR. Patients with high or medium expression had an objective response rate of 9/25 (36%)...CT900 exhibited an acceptable side effect profile with clinical benefit in patients with high/medium α-FR expression...
DOI:
https://doi.org/10.1158/1078-0432.CCR-22-1268
Source:
Title:
A phase I trial a FR alpha targeted thymidylate synthase inhibitor CT900 exploring four schedules of treatment in expansion cohorts of patients with high-grade serous ovarian cancer.
Published date:
05/13/2020
Excerpt:
The CA125 response rate in all patients within cohort B was 13/25 (52%) and 10/16 (63%) in patients with high/medium FRα expression.
DOI:
10.1200/JCO.2020.38.15_suppl.6043
Trial ID:
